SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_26352_sm_SuppFig1.tif205KSupporting Information Figure 1. eIF3I and Akt1 interaction is phosphorylation-dependent. (A) Treatment of calf-intestinal alkaline phosphatase (CIP) reduced interaction of overexpressed- eIF3I and Akt1 in 293T cells. (B) Treatment of Insulin-like growth factor 1 (IGF-1) to 293T transfectants of eIF3I and Akt1 increased phosphorylation of Akt1 and its interaction with eIF3I.
HEP_26352_sm_SuppFig2.tif126KSupporting Information Figure 2. eIF3I interrupted Akt1 protein interactions with PP2A. Akt1 can interact with PP2A-B and PP2A-C in 293 cells but loss their protein interactions when co- transfection with eIF3I. Tubulin served as protein loading control.
HEP_26352_sm_SuppFig3.tif231KSupporting Information Figure 3. eIF3I is not an Akt1 substrate. (A) Autoradiography of in vitro 32P-labeled kinase assay: detection of phosphorylated protein in immunoprecipitated complex in 293 cells with constitutively active Akt1 (myr-Akt1). (B) Detection of Akt1 phospho-substrate signal in HA-precipitated immune-complexes in 293T cells. Western blotting analysis of abovementioned proteins and tubulin served as expression and internal controls in lower panels.
HEP_26352_sm_SuppFig4.tif131KSupporting Information Figure 4. The subcellular localization of eIF3I-activated Akt1. Akt1 and eIF3I proteins are mainly localized in cytoplasm fraction and detectable in fractions of plasma membrane and nucleus. Tubulin, E-cadherin and histone H3 protein expression served as localization controls of cytoplasm, membrane and nucleus respectively.
HEP_26352_sm_SuppFig5.tif208KSupporting Information Figure 5. Growth effect of sorafenib treatments on eIF3I-overexpressed HepG2 cells. Gray and full columns represent the cell proliferation activity of eIF3I-overexpressed and vector only HepG2 transfectants, respectively, treated with various doses (0∼10 μM) of sorafenib for 2 days.
HEP_26352_sm_SuppTab1.doc105KSupporting Information Table 1. Clinical features and immunohistochemistry results of eIF3I and pAKT1 antibodies of 59 HCC patients.
HEP_26352_sm_SuppInfo.doc88KSupporting Information Figure 1.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.